Literature DB >> 16395700

Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study.

Ola Landgren1, Martha S Linet, Mary L McMaster, Gloria Gridley, Kari Hemminki, Lynn R Goldin.   

Abstract

A population-based case-control study was conducted to evaluate risk of developing multiple myeloma (MM) associated with personal history of autoimmune diseases and occurrence of autoimmune and selected hematologic disorders in first-degree relatives. Data were obtained for all (n = 8,406) MM cases diagnosed in Sweden (1958-1998), with linkable relatives, 16,543 matched controls and first-degree relatives of cases (n = 22,490) and controls (n = 44,436). Odds ratios (ORs) were calculated to quantify the risk of MM in relation to personal/family history of 32 autoimmune disorders. Familial aggregation of malignancies was evaluated in a marginal survival model using relatives as the cohort. The risk for MM was significantly elevated among subjects with a personal history of pernicious anemia (OR = 3.27; 2.22-4.83) and individuals with a family history of systemic lupus erythematosus (OR = 2.66; 1.12-6.32). Compared with controls, relative risk (RR) of MM was significantly increased (RR = 1.67; 1.02-2.73) in relatives of cases, particularly relatives of probands aged > or =65 at diagnosis (RR = 2.50; 1.19-5.27). Risks were nearly 4-fold elevated among female relatives (RR = 3.97; 1.54-10.2) and among relatives of female probands (RR = 3.74; 1.58-8.83). MM cases had more cases of monoclonal gammopathy of undetermined significance (MGUS) among their relatives than controls, but the numbers were too small to be conclusive. There was generally no increase in risk of MM in probands whose relatives had hematologic malignancies other than MM. These findings do not support a strong association between personal/familial autoimmune diseases and MM. However, MM itself shows significant familial aggregation, implicating the etiologic importance of this type of hematological neoplasm and perhaps MGUS in germ line genes. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16395700     DOI: 10.1002/ijc.21745

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  48 in total

1.  Familial Aspects of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and Related Lymphomas.

Authors:  Lynn R Goldin; Ola Landgren; Gerald E Marti; Neil E Caporaso
Journal:  European J Clin Med Oncol       Date:  2010-02

2.  Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies.

Authors:  Lesley A Anderson; Shahinaz Gadalla; Lindsay M Morton; Ola Landgren; Ruth Pfeiffer; Joan L Warren; Sonja I Berndt; Winnie Ricker; Ruth Parsons; Eric A Engels
Journal:  Int J Cancer       Date:  2009-07-15       Impact factor: 7.396

3.  Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-06-22       Impact factor: 9.941

Review 4.  Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Jill Koshiol; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

Review 5.  Host genetics in follicular lymphoma.

Authors:  James R Cerhan
Journal:  Best Pract Res Clin Haematol       Date:  2011-05-05       Impact factor: 3.020

6.  Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma.

Authors:  Normann Steiner; Georg Göbel; Daniela Michaeler; Anna-Luise Platz; Wolfgang Prokop; Anna Maria Wolf; Dominik Wolf; Christina Duftner; Eberhard Gunsilius
Journal:  Blood Adv       Date:  2021-03-23

Review 7.  Second malignancies in multiple myeloma; emerging patterns and future directions.

Authors:  Kylee Maclachlan; Benjamin Diamond; Francesco Maura; Jens Hillengass; Ingemar Turesson; C Ola Landgren; Dickran Kazandjian
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-11       Impact factor: 3.020

8.  Atypical sarcoidosis diagnosed by bone marrow biopsy during renal workup for possible multiple myeloma.

Authors:  Amr El-Husseini; Alberto J Sabucedo; Jorge Lamarche; Craig Courville; Alfredo Peguero
Journal:  CEN Case Rep       Date:  2012-12-11

9.  Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden.

Authors:  Ola Landgren; Sigurdur Y Kristinsson; Lynn R Goldin; Neil E Caporaso; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Magnus Bjorkholm; Ingemar Turesson
Journal:  Blood       Date:  2009-01-30       Impact factor: 22.113

10.  Familial multiple myeloma: report on two families and discussion of screening options.

Authors:  Erica H Gerkes; Mirjam M de Jong; Rolf H Sijmons; Edo Vellenga
Journal:  Hered Cancer Clin Pract       Date:  2007-06-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.